Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

James Abel

Psychiatry Fairmont, WV Medical Doctor

NPI 1376729244 CMS profile 108115

1228 Country Club Rd, Suite 800, Fairmont, WV 26554

Open in the dashboard

General payments

$1,021

76 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, James Abel of Fairmont, WV is reported in the CMS Open Payments database as having received $1,021 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $201 11
2019 General $821 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Abel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to James Abel were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year James Abel Psychiatry median Middle half National median
2019 $821 $184 $59–$605 $163
2020 $201 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Janssen Pharmaceuticals, Inc $304 20 payments
  2. Otsuka America Pharmaceutical, Inc. $228 15 payments
  3. Vanda Pharmaceuticals Inc. $145 12 payments
  4. Allergan Inc. $142 17 payments
  5. Lundbeck LLC $66 4 payments
  6. Teva Pharmaceuticals USA, Inc. $48 3 payments
  7. Alkermes, Inc. $37 2 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $34 2 payments
  9. Neurocrine Biosciences, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $1,021 76 payments
Products named General payments · program years 2019–2020
  1. INVEGA SUSTENNA $246 17 payments
  2. ABILIFY MAINTENA $195 13 payments
  3. SPRAVATO $168 12 payments
  4. FANAPT $145 12 payments
  5. HETLIOZ $145 12 payments
  6. VRAYLAR $142 17 payments
  7. INVEGA TRINZA $122 8 payments
  8. REXULTI Psychiatry $48 3 payments
  9. AUSTEDO $48 3 payments
  10. REXULTI Psychiatry $33 2 payments
  11. Other $170 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

3,559

Median for Psychiatry: 574

Drug cost

$347,960

Median for Psychiatry: $27,624

Branded share of claims

17.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 44 $133,892
Invega Trinza Paliperidone Palmitate Brand 11 $96,978
Latuda Lurasidone Hcl Brand 11 $23,419
Vraylar Cariprazine Hcl Brand 12 $19,568
Paliperidone Er Paliperidone Brand 52 $6,588
Saphris Asenapine Maleate Brand 11 $6,005
Clozapine Generic 94 $5,517
Myrbetriq Mirabegron Brand 12 $5,046
Belsomra Suvorexant Brand 12 $4,715
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 94 $3,056

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$5,739

Medicare's payments for the services billed

Medicare patients

51

Average age 55

Services billed

162

26 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 63%
High blood pressure 55%
Arthritis 47%
Diabetes 29%
COPD 25%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record